Trevitt, Benjamin T.
Bailey, Sasha
Mills, Llewelyn
Arkell, Thomas
McGregor, Iain S.
Lintzeris, Nicholas
Article History
Received: 14 December 2025
Accepted: 9 June 2026
First Online: 3 July 2026
Declarations
:
: This study was approved by the Sydney University Human Research Ethics Committee (2022/433). In order to begin the survey respondents were asked to read a linked Participant Information Statement and to tick a check box giving consent for their data to be used in the study.
: Not applicable.
: Prof Lintzeris reports grants from the Australian National Health and Medical Research Council (NHMRC) during the conduct of the study; and research grants from Camurus and Indivior for unrelated work. Prof McGregor reports grants from NHMRC and grants from Lambert Initiative for Cannabinoid Therapeutics during the conduct of the study for projects unrelated to the submitted work; Prof McGregor has patents to WO2018107216A1, WO2017004674A1, and WO2011038451A1 issued and licensed, and patents to AU2017904438, AU2017904072, and AU2018901971 pending. No other authors report conflicts of interest.